Browse MYO7B

Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cell projection, microvillus Note=Enriched in the microvilli of the intestinal brush border.
Domain PF00373 FERM central domain
PF00612 IQ calmodulin-binding motif
PF00063 Myosin head (motor domain)
PF00784 MyTH4 domain
PF07653 Variant SH3 domain
Function

Myosins are actin-based motor molecules with ATPase activity. Their highly divergent tails are presumed to bind to membranous compartments, which would be moved relative to actin filaments. As part of the intermicrovillar adhesion complex/IMAC plays a role in epithelial brush border differentiation, controlling microvilli organization and length. May link the complex to the actin core bundle of microvilli (Probable).

> Gene Ontology
 
Biological Process GO:1904970 brush border assembly
Molecular Function GO:0003774 motor activity
GO:0003779 actin binding
Cellular Component GO:0005902 microvillus
GO:0005903 brush border
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0045177 apical part of cell
GO:0090651 apical cytoplasm
GO:0098858 actin-based cell projection
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYO7B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYO7B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYO7B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4610.163
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9110.139
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1150.792
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1260.846
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1750.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5070.858
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8330.144
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.580.059
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0360.968
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2910.831
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2340.479
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4330.0835
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYO7B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.52.715.80.0147
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.53.415.10.0291
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472528.6-3.61
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO7B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO7B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO7B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO7B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYO7B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYO7B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYO7B
Namemyosin VIIB
Aliases myosin-VIIb; Unconventional myosin-VIIb
Chromosomal Location2q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYO7B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.